Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2022 | 12-2021 | 09-2021 | 06-2021 | 03-2021 | |
| Sales | 2,965,100 | 4,951,700 | 3,452,800 | 5,138,500 | 2,528,700 |
| Cost of Goods | 404,900 | 982,600 | 453,200 | 693,700 | 308,000 |
| Gross Profit | 2,560,200 | 3,969,100 | 2,999,600 | 4,444,800 | 2,220,700 |
| Operating Expenses | 1,302,600 | 1,330,000 | 1,152,600 | 1,098,300 | 1,108,000 |
| Operating Income | 1,258,500 | 2,639,700 | 1,847,200 | 3,347,200 | 1,112,700 |
| Interest Expense | 13,600 | 14,100 | 14,200 | 14,400 | 14,600 |
| Other Income | -183,800 | -122,200 | -16,400 | 420,000 | 154,900 |
| Pre-tax Income | 1,061,100 | 2,503,400 | 1,816,600 | 3,752,800 | 1,253,000 |
| Income Tax | 87,600 | 274,400 | 184,400 | 653,900 | 137,800 |
| Net Income Continuous | 973,500 | 2,229,000 | 1,632,200 | 3,098,900 | 1,115,200 |
| Net Income | $973,500 | $2,229,000 | $1,632,200 | $3,098,900 | $1,115,200 |
| EPS Basic Total Ops | 9.12 | 20.94 | 15.37 | 29.51 | 10.58 |
| EPS Basic Continuous Ops | 9.12 | 20.94 | 15.37 | 29.51 | 10.58 |
| EPS Diluted Total Ops | 8.61 | 19.58 | 14.33 | 27.97 | 10.09 |
| EPS Diluted Continuous Ops | 8.61 | 19.58 | 14.33 | 27.97 | 10.09 |
| EBITDA(a) | $1,332,800 | $2,714,200 | $1,920,400 | $3,418,300 | $1,180,100 |